News
Eir Genix Showcases Dual-Track Biosimilars and CDMO Strategy in U. S. Market Push at BIO 2026 | Digital More
2+ hour, 59+ min ago (302+ words) Eir Genix showcases its complete HER2-positive breast cancer biosimilar product portfolio and one-stop integrated CDMO platform at BIO 2026. Image: Gene Online Breast Cancer Remains a Core Battlefield in Oncology Innovation According to the World Health Organization (WHO), approximately 2. 3 million women…...
Symbols: btc-usd,cnq.to,cve.to,nasdaq:eikn,asx:tlx,nasdaq:tlx